
---
title: '康希诺掉落的千亿金冠'
categories: 
 - 新媒体
 - 果壳网
 - 科学人
headimg: 'https://2-im.guokr.com/obDFr0_BZrEkG8DMbwz9dt-L09KkCZ2OM19zdDnPs39yAwAAzAEAAFBO.png?imageView2/1/w/555/h/289'
author: 果壳网
comments: false
date: Thu, 02 Sep 2021 02:06:46 GMT
thumbnail: 'https://2-im.guokr.com/obDFr0_BZrEkG8DMbwz9dt-L09KkCZ2OM19zdDnPs39yAwAAzAEAAFBO.png?imageView2/1/w/555/h/289'
---

<div>   
<section style="font-size: 15px;color: rgb(62, 62, 62);letter-spacing: 1.5px;line-height: 2.25;padding: 0px 8px;box-sizing: border-box;font-style: normal;font-weight: 400;text-align: justify;" data-mpa-powered-by="yiban.io"><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">510倍。这样的业绩增长数据，在上市公司财报中可不常见，但科创板的生物医药公司康希诺（SH688185）做到了。</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">8月30日，公司发布的2021年半年报显示，期内实现营收20.61亿元，同比增长51058%；同期归母净利润达9.37亿元，去年同期则为亏损1亿，成功扭亏为盈<sup style="box-sizing: border-box;">[1]</sup>。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">这个成绩真是——哇哦！</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br></p><p style="letter-spacing: 1.5px;white-space: normal;color: rgb(219, 175, 105);font-size: 13px;text-align: right;">陈闷雷丨作者</p><p style="letter-spacing: 1.5px;white-space: normal;color: rgb(219, 175, 105);font-size: 13px;text-align: right;">屈怡春丨资料</p><p style="letter-spacing: 1.5px;white-space: normal;color: rgb(219, 175, 105);font-size: 13px;text-align: right;">李拓丨编辑</p><p style="letter-spacing: 1.5px;white-space: normal;color: rgb(219, 175, 105);font-size: 13px;text-align: right;">放大灯团队丨策划</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><span style="color: rgb(62, 62, 62);font-size: 15px;letter-spacing: 1.5px;">过去一年多，康希诺的新冠疫苗“克威莎”（Ad5-nCoV）曾创下多项行业纪录：</span><span style="color: rgb(62, 62, 62);font-size: 15px;letter-spacing: 1.5px;">在技术路线上，它是国内唯一的单针法新冠疫苗，不仅在国内率先进入临床试验，在世界范围也第一个开启Ⅱ期临床试验；</span><span style="color: rgb(62, 62, 62);font-size: 15px;letter-spacing: 1.5px;">在产业领域，它是最早开启出口谈判的国产新冠疫苗，也是让康希诺扭亏为盈的唯一产品。</span><span style="color: rgb(62, 62, 62);font-size: 15px;letter-spacing: 1.5px;">在多重利好与市场情绪共同推动下，公司的A股市值在六月下旬，曾一度攀至近2000亿的高点。</span></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">可之后的走势完全就是另一种“哇哦”了。自7月以来，康希诺股价一路狂泻，短暂反弹恐怕只是套住了更多看走眼的投资者。截至8月最后一个交易日，康希诺股价报收385.23元，较798元的高点腰斩，还多饶了一点儿，A股市值也不足1000亿。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.521542" data-src="https://2-im.guokr.com/obDFr0_BZrEkG8DMbwz9dt-L09KkCZ2OM19zdDnPs39yAwAAzAEAAFBO.png" data-type="png" data-w="882" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;" src="https://2-im.guokr.com/obDFr0_BZrEkG8DMbwz9dt-L09KkCZ2OM19zdDnPs39yAwAAzAEAAFBO.png?imageView2/1/w/555/h/289" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">这是咋了？ 疫苗的故事突然不好听了吗？</p><p style="color: rgb(219, 175, 105);font-size: 13px;letter-spacing: 1.5px;text-align: right;white-space: normal;"><br></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">导致康希诺股价狂跌的原因很多。既有礼来系大股东“清仓式”减持（套现超36亿）<sup style="font-size: 12px;box-sizing: border-box;">[2]</sup>，摩根大通等外资减持<sup style="font-size: 12px;box-sizing: border-box;">[3]</sup>带来的巨大抛售压力，也有此前炒得太高导致的回调，总之走势令股民心头滴血。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">此前，康希诺曾公布了上市后的第一份年报，可当时其新冠疫苗“克威莎”尚未获批，没有实质业务，看个热闹都嫌多。而从2021年2月至今，疫苗业务已经正式展开并大量创收，在如此重要的时间节点，康希诺发布的这份半年财报，数字很美，却很难让人给出积极评价：投资者真正关心的内容，财报透露极为有限，诚意欠奉。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">虽说交易所对半年报的信披要求确实不高，但公司是不是应该更主动一些，而不是仅仅合规就好？</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;width: 12.5%;height: auto;box-sizing: border-box;"><img data-ratio="1" data-src="https://2-im.guokr.com/gWoGcpBA_s-aV5CH5hpkWzp5jF0b16EaUxYp1FUvFSxkAAAAZAAAAFBO.png" data-type="png" data-w="100" style="vertical-align: middle;max-width: 100%;width: 100%;box-sizing: border-box;" width="100%" src="https://2-im.guokr.com/gWoGcpBA_s-aV5CH5hpkWzp5jF0b16EaUxYp1FUvFSxkAAAAZAAAAFBO.png" referrerpolicy="no-referrer"></section></section><section style="max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: flex;justify-content: center;align-items: center;flex-direction: column;max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;box-sizing: border-box;"><section style="display: flex;padding: 3px 0px;flex-direction: column;justify-content: center;border-bottom: 2px dashed rgb(219, 175, 105);max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="text-align: unset;background-color: rgb(255, 206, 0);padding-left: 15px;padding-right: 15px;padding-top: 1px;max-width: 100%;font-size: 16px;color: rgb(17, 17, 17);box-sizing: border-box;"><p style="margin: 0px;padding: 0px;box-sizing: border-box;"><strong style="box-sizing: border-box;">产能疑云</strong></p></section></section></section></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">赚了20亿，确实很多，但康希诺对一组重要数据讳莫如深——公司的产能利用率到底怎么样？</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">放大灯团队曾发布《<a href="https://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650145142&idx=1&sn=a5dbf435928b0617fc3c31f1ea37c6a3&scene=21#wechat_redirect" target="_blank" style="box-sizing: border-box;" data-linktype="2">康希诺的两次探险</a>》和《<a href="https://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650146176&idx=1&sn=b436576d2920ed8abc56248bf9a4d549&scene=21#wechat_redirect" target="_blank" style="box-sizing: border-box;" data-linktype="2">在外国“翻车”的疫苗，国内还有戏吗？</a>》，质疑康希诺的产能和交付进度，而今，在康希诺的半年报中，相关信息依然付之阙如。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">尽管公开信息显示，康希诺现有疫苗产能约为2亿，全年预计可达5亿，但关键问题是，<strong style="box-sizing: border-box;"><span style="background-color: rgb(255, 206, 0);box-sizing: border-box;">有产能不代表就可以满产满销</span></strong>（新近披露的会议纪要显示，即使到2022年，就算真有5亿账面产能也要打七五到八折<sup style="font-size: 12px;box-sizing: border-box;">[4]</sup>）。要知道除了原液生产与灌装能力外，中硼硅玻璃瓶、外部包材都是最终产量的关键影响因素，而全球供应链巨震，各环节的供应短缺都使疫苗最终产能掣肘。就连官方也承认，在新冠疫苗生产过程中，遇到了原料供应和技术不稳定的问题<sup style="font-size: 12px;box-sizing: border-box;">[4]</sup>。因此，<strong style="box-sizing: border-box;"><span style="color: rgb(62, 62, 62);background-color: rgb(255, 206, 0);box-sizing: border-box;">直接将产能等同于公司的营收，显然过于乐观</span></strong>。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">当前有关康希诺疫苗的具体信息不多，采购价格也尚不透明，所以我们只能与其它公司做个对比，来推断公司的具体情况。</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">在同一天披露财报的除了康希诺，还有另一家疫苗供应商智飞生物（SZ300122），后者研发的三针剂重组蛋白亚单位新冠疫苗“智克威得”，已在多个省份展开接种<sup style="box-sizing: border-box;">[5]</sup>。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">财报显示，智飞生物期内自主产品总营收60.37亿元（同比增长1475%），全资子公司安徽智飞龙科马负责新冠疫苗的研发与生产销售，由于该子公司并无其它实质性在售产品，所以在2021年上半年实现的53.13亿元营收，主要来自新冠疫苗。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.2638681" data-src="https://3-im.guokr.com/daCSKzTgfUf1Yk7N3R2v4jManAFA1b1MTpYihl4QzB-bAgAAsAAAAFBO.png" data-type="png" data-w="667" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;" src="https://3-im.guokr.com/daCSKzTgfUf1Yk7N3R2v4jManAFA1b1MTpYihl4QzB-bAgAAsAAAAFBO.png?imageView2/1/w/555/h/146" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">那么康希诺的疫苗收入是多少呢？差不多20亿，比智飞少了30亿左右。不过康希诺获批使用，要早于智飞：</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><ul class="list-paddingleft-2" style="list-style-type: disc;box-sizing: border-box;"><li style="box-sizing: border-box;"><p style="margin: 0px;padding: 0px;box-sizing: border-box;">2021年2月25日，国家药监局附条件批准康希诺生物股份公司重组新型冠状病毒疫苗（5型腺病毒载体）注册申请，附条件批准上市注册申请。<sup style="box-sizing: border-box;">[6] </sup></p></li></ul></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><ul class="list-paddingleft-2" style="list-style-type: disc;box-sizing: border-box;"><li style="box-sizing: border-box;"><p style="margin: 0px;padding: 0px;box-sizing: border-box;">2021年3月17日，重庆智飞生物制品股份有限公司发布公告称，全资子公司安徽智飞龙科马生物制药有限公司与中国科学院微生物研究所合作研发的重组新冠疫苗，经国家卫生健康委提出建议，国家药品监督管理局组织论证同意紧急使用。<sup style="box-sizing: border-box;">[7] </sup></p></li></ul></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">有如此差距，还要归咎于康希诺底子实在太差。虽然官方临床试验好消息不断，但产能建设进度不会说谎：直到今年4月底，康希诺才在天津真正建成了自有生产线<sup style="font-size: 12px;box-sizing: border-box;">[8]</sup>。显然受研发的不确定性影响，公司必须等待疫苗有相对积极的临床结果，才能布局生产线的建设。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">反观智飞，作为比较成熟的疫苗生产商，公司产线众多，可以直接调用已建成产能：在去年10月份，智飞生物就开始规划新冠疫苗产线，提前储备了约80万人份/天的产能<sup style="font-size: 12px;box-sizing: border-box;">[9]</sup>。而根据早先报道，智飞早在5月中下旬，就已经生产了超过1亿支疫苗，日产超100万剂。<sup style="font-size: 12px;box-sizing: border-box;">[5]</sup></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">至于康希诺，公司近日在中报投资者会议中表示，疫苗产品“克威莎”覆盖了国内约1000万人<sup style="font-size: 12px;box-sizing: border-box;">[4]</sup>。这一数据相较于灭活疫苗数亿的接种量少得可怜。<strong style="box-sizing: border-box;"><span style="color: rgb(62, 62, 62);background-color: rgb(255, 206, 0);box-sizing: border-box;">相比之下，科兴的新冠灭活疫苗“克尔来福”（CoronaVac），在6月的日产能就已突破千万<sup style="font-size: 12px;box-sizing: border-box;">[10]</sup>，两天就能实现同等规模的人群覆盖。</span></strong></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.1643192" data-src="https://2-im.guokr.com/R-oAJHkEsN6t-x-nMDZFVc4rPjmcFxZzU7uIMCiZB6UpBAAArwAAAFBO.png" data-type="png" data-w="1065" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;" src="https://2-im.guokr.com/R-oAJHkEsN6t-x-nMDZFVc4rPjmcFxZzU7uIMCiZB6UpBAAArwAAAFBO.png?imageView2/1/w/555/h/91" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">官方在半年报会议交流中已经提及的产能影响因素，包括天津生产线遇到“原料供应”“技术不稳定”和“产能爬坡”问题<sup style="font-size: 12px;box-sizing: border-box;">[4]</sup>。依照公司声称的现有产能（2亿）计算，康希诺的月产能应当超过1600万。若真是如此，表明公司产能的利用率十分堪忧。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(62, 62, 62);background-color: rgb(255, 206, 0);box-sizing: border-box;">这正是资本市场最忌讳的“不确定性”。</span></strong>智飞与康希诺两家上市公司的股价，会收获截然不同的走势，也就不难理解了。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(62, 62, 62);background-color: rgb(255, 206, 0);box-sizing: border-box;">这种信息不透明，对普通投资者也不公平。</span></strong>投资市场的机构有更灵通的消息渠道，有线下调研的能力，可普通投资者呢？总不能跑到生产车间去尽调吧？在信息披露不够详尽的情况下，别说是做赚钱的决策了，不赔钱都难。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">如果有可能，康希诺目前最应该做的，是学智飞那样，尽快公开产能，否则只能任由市场胡乱猜测。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">本文核心目的不是为了唱衰，只是希望读者能够更理性看待一个明显过热的行业。因为历史反复证明，资本市场向来十分悲观，稍有些风吹草动跑得比谁都快。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;width: 12.5%;height: auto;box-sizing: border-box;"><img data-ratio="1" data-src="https://3-im.guokr.com/t_2VU7afR1YullhPHgxGWT0UkiE6ygDGa3YQcCrkg75kAAAAZAAAAFBO.png" data-type="png" data-w="100" style="vertical-align: middle;max-width: 100%;width: 100%;box-sizing: border-box;" width="100%" src="https://3-im.guokr.com/t_2VU7afR1YullhPHgxGWT0UkiE6ygDGa3YQcCrkg75kAAAAZAAAAFBO.png" referrerpolicy="no-referrer"></section></section><section style="max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: flex;justify-content: center;align-items: center;flex-direction: column;max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;box-sizing: border-box;"><section style="display: flex;padding: 3px 0px;flex-direction: column;justify-content: center;border-bottom: 2px dashed rgb(219, 175, 105);max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="text-align: unset;background-color: rgb(255, 206, 0);padding-left: 15px;padding-right: 15px;padding-top: 1px;max-width: 100%;font-size: 16px;color: rgb(17, 17, 17);box-sizing: border-box;"><p style="margin: 0px;padding: 0px;box-sizing: border-box;"><strong style="box-sizing: border-box;">新冠疫苗能吃一辈子吗？</strong></p></section></section></section></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">现在讨论新冠疫情何时结束，显然已无意义，动态防控将是长期趋势。随着一个比一个凶猛的变异病毒迭出，疫苗保护效力又遭到挑战，“加强针”的概念应运而生。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">这对康希诺是利好吗？尚难定论。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">首先，加强针到底有没有必要，目前仍在讨论阶段。但从总的政策导向上看，加强针的施打必要性不大，在8月27日国务院联防联控机制发布会上，官方态度也相对明确：“目前我国疫情防控形势很好，重点是外防输入。”<sup style="font-size: 12px;box-sizing: border-box;">[11]</sup>即使有必要，也要在完成第二针接种六个月后施行，且接种范围相对集中于输入风险高的海关、边检、航空、隔离点、定点医疗机构等工作人员。真的强制或全员加强接种的可能性也不高。</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">其次，即使要打加强针，还要讨论能否混打的问题，即同一位接种者，能否接种不同技术路线的疫苗（mRNA、重组蛋白、腺病毒、灭活等）。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">这一点对康希诺的影响可就大了。国内只接种了1000万的康希诺腺病毒疫苗，接种比例太低，<strong style="box-sizing: border-box;"><span style="color: rgb(62, 62, 62);background-color: rgb(255, 206, 0);box-sizing: border-box;">一旦确定不能混打，那公司在国内的增量十分堪忧</span></strong>。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">目前，专业人士对混打的看法仍有明显分歧。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">世界卫生组织方面的态度是，目前尚没有足够临床数据支持混打<sup style="box-sizing: border-box;">[12]</sup>。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.2568203" data-src="https://3-im.guokr.com/iLnCYp-cbM-ES8be3ejEu0q4JvsRKfBe9gCYWGMM1k8nBAAAEQEAAFBO.png" data-type="png" data-w="1063" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;" src="https://3-im.guokr.com/iLnCYp-cbM-ES8be3ejEu0q4JvsRKfBe9gCYWGMM1k8nBAAAEQEAAFBO.png?imageView2/1/w/555/h/142" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">世界卫生组织首席科学家之一，Swaminathan博士则在早先明确表态，“混打”是一种危险的趋势（dangerous trend）。她进一步解释称，至少“混打”疫苗的决定不应由个人决定，而是各国卫生部门依靠数据给出相应决策，但相关数据仍待补充<sup style="box-sizing: border-box;">[13]</sup>。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">美国CDC则直接表示不支持混打，即使是相同技术路线的也不建议<sup style="box-sizing: border-box;">[14]</sup>。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.3222222" data-src="https://1-im.guokr.com/Zn0yH0EZpoDrYviHwd5YE-HgNsnt9ppq1jNdNAdK1AQ4BAAAXAEAAFBO.png" data-type="png" data-w="1080" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;" src="https://1-im.guokr.com/Zn0yH0EZpoDrYviHwd5YE-HgNsnt9ppq1jNdNAdK1AQ4BAAAXAEAAFBO.png?imageView2/1/w/555/h/178" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">但另一方面，一些正在进行的试验表明，疫苗混打带来了更强的免疫效果。不过这些数据要么来自小范围临床试验，要么是动物实验，尚没有表现出能够推动全球性决策转变的能力<sup style="box-sizing: border-box;">[15][16]</sup>。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.3023256" data-src="https://1-im.guokr.com/EQfNLmxIwGCPDl5E9urKgEvb0SAwimJ9WfDUj8SKen6yAwAAHgEAAFBO.png" data-type="png" data-w="946" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;" src="https://1-im.guokr.com/EQfNLmxIwGCPDl5E9urKgEvb0SAwimJ9WfDUj8SKen6yAwAAHgEAAFBO.png?imageView2/1/w/555/h/167" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.2202381" data-src="https://3-im.guokr.com/BuINNSN1vkP8C8qGZaVauXj7UT8T-ySw4jZSy_1O0YtIAwAAuQAAAFBO.png" data-type="png" data-w="840" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;" src="https://3-im.guokr.com/BuINNSN1vkP8C8qGZaVauXj7UT8T-ySw4jZSy_1O0YtIAwAAuQAAAFBO.png?imageView2/1/w/555/h/122" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">总而言之，现在断定“加强针代表未来新的强劲增长点”，还为时过早。<strong style="box-sizing: border-box;"><span style="color: rgb(62, 62, 62);background-color: rgb(255, 206, 0);box-sizing: border-box;">对所有技术路线的新冠疫苗“加强针”概念和市场前景，我们都应持更谨慎的态度。</span></strong></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">那么，正处于临床试验Ⅲ期的康希诺吸入式新冠疫苗，还值得关注吗？</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">从接种进度来看，到8月31日，国内接种的新冠疫苗已经累计超过20.5亿剂<sup style="box-sizing: border-box;">[17]</sup>，出口都超过11亿剂，吸入式疫苗这种既没有获批，也没有产能，更没有实际订单的“空气肌肉”，对资本市场实在无法产生有效刺激。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">疫情都快两周年了，新冠疫苗市场，早已不愿“听故事”，只想“看成果”。截至8月19日，世界卫生组织紧急使用清单/资格预审的在列新冠疫苗有24种<sup style="box-sizing: border-box;">[18]</sup>，新冠疫苗到底能否成一种类似流感疫苗的长期生意，归根结底还得看各家疫苗的效力、产能和未来份额。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">如果没有产能，那又如何翻身呢？</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;width: 12.5%;height: auto;box-sizing: border-box;"><img data-ratio="1" data-w="100" data-src="https://2-im.guokr.com/19G2AqGGFnu9CT14tllYASRSxFCg8jkiGW0IOgs9A51kAAAAZAAAAFBO.png" style="vertical-align: middle;max-width: 100%;width: 100%;box-sizing: border-box;" data-type="png" width="100%" src="https://2-im.guokr.com/19G2AqGGFnu9CT14tllYASRSxFCg8jkiGW0IOgs9A51kAAAAZAAAAFBO.png" referrerpolicy="no-referrer"></section></section><section style="max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: flex;justify-content: center;align-items: center;flex-direction: column;max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;box-sizing: border-box;"><section style="display: flex;padding: 3px 0px;flex-direction: column;justify-content: center;border-bottom: 2px dashed rgb(219, 175, 105);max-width: 100%;box-sizing: border-box;"><section style="display: inline;max-width: 100%;box-sizing: border-box;" powered-by="xiumi.us"><section style="text-align: unset;background-color: rgb(255, 206, 0);padding-left: 15px;padding-right: 15px;padding-top: 1px;max-width: 100%;font-size: 16px;color: rgb(17, 17, 17);box-sizing: border-box;"><p style="margin: 0px;padding: 0px;box-sizing: border-box;"><strong style="box-sizing: border-box;">谁带康希诺接着飞？</strong></p></section></section></section></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">就没点儿好消息吗？有。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">首先，康希诺的新冠疫苗已实现商业化。至少在未来一段时间，公司不愁实质性业务，而且这一业务的盈利能力也很强，强大的自造血能力可以为未来发展提供有力支撑，更有底气的烧钱搞研发。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">其次，康希诺的A群C群脑膜炎球菌多糖结合疫苗（简称MCV2）已获批上市，这是公司除新冠疫苗外，第三款真正意义上实现商业化的疫苗产品（第一款是埃博拉疫苗，但该产品商业化潜力太弱）。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">6月23日，公司发公告宣布MCV2疫苗获批。当天市场反馈相当积极，康希诺股价迅速拉涨，涨幅一度超过17%，且其股价正是在这一天达到了历史新高。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">这个好消息并不纯粹，几天后一路狂泄的股价说明了不少问题。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.7832647" data-src="https://2-im.guokr.com/1FhKTduGUlotidmKRvmc-xBXc8oTYqL9XnyMcq_cUBjZAgAAOwIAAFBO.png" data-type="png" data-w="729" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;" src="https://2-im.guokr.com/1FhKTduGUlotidmKRvmc-xBXc8oTYqL9XnyMcq_cUBjZAgAAOwIAAFBO.png?imageView2/1/w/555/h/434" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">从世界卫生组织的观点看，结合疫苗（Conjugate Vaccine）较传统的多糖疫苗（Polysaccharide Vaccine）具有显著优势。早在2002年，临床数据就已经充分证明，结合疫苗的保护能力要明确优于多糖疫苗，其具备潜在的群体保护效应和较高的免疫原性，尤其是对2岁以下的儿童。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">因此，从专业性和技术的角度看，MCV2疫苗无疑合格。但问题是，这款产品有竞争力吗？</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">根据药监局披露信息，市面上已经有多款国产MCV2获批，且不乏智飞、沃森这样的成熟企业，康希诺的同类产品竞争力几何，很难说。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.7546296" data-src="https://2-im.guokr.com/IE7MW4Uht1QZ72LAbWMda2bRq3yCaRx6zhSTbA8Fc6s4BAAALwMAAFBO.png" data-type="png" data-w="1080" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;" src="https://2-im.guokr.com/IE7MW4Uht1QZ72LAbWMda2bRq3yCaRx6zhSTbA8Fc6s4BAAALwMAAFBO.png?imageView2/1/w/555/h/418" referrerpolicy="no-referrer"></section></section><section style="text-align: center;font-size: 12px;color: rgb(219, 175, 105);box-sizing: border-box;" powered-by="xiumi.us"><p style="margin: 0px;padding: 0px;box-sizing: border-box;">信息来源丨国家药品监督管理局官网数据<sup style="box-sizing: border-box;"> [19]</sup></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><span style="color: rgb(62, 62, 62);font-size: 15px;letter-spacing: 1.5px;">实际上，康希诺目前具备独特性的产品是另一款MCV4（ACYW135 群脑膜炎球菌四价结合疫苗），但这款疫苗距离获批上市还需要一定时间，且在国外多家疫苗巨头也早已将此类疫苗商业化。</span></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">于是我们又回到了问题原点：<strong style="box-sizing: border-box;"><span style="color: rgb(62, 62, 62);background-color: rgb(255, 206, 0);box-sizing: border-box;">在产能不占优，技术不占优，渠道不占优的情况下，康希诺用什么吸引采购方购买他们的产品？</span></strong>更何况，现阶段的脑膜炎结合疫苗仍属二类疫苗，即由公民自费并且自愿受种的其它疫苗，这意味着产品需要经过非常充分的市场考验，这很可能加剧了康希诺的推广难度。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">有一款具有较大商业潜力的产品获批上市，值得庆祝，但对康希诺未来发展助力几何，还需要先看看市场的脸色。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">谁都可能有飞的机会，但想不摔下来，还是要有点儿真本事。</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.6287037" data-src="https://3-im.guokr.com/QOq0SbEi1w7HECAYB0GrglDXSHPplisstb6L649ozgA4BAAApwIAAFBO.png" data-type="png" data-w="1080" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;" src="https://3-im.guokr.com/QOq0SbEi1w7HECAYB0GrglDXSHPplisstb6L649ozgA4BAAApwIAAFBO.png?imageView2/1/w/555/h/348" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="margin-top: 10px;margin-bottom: 10px;text-align: center;justify-content: center;opacity: 0.9;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: inline-block;width: 90%;border-color: rgb(219, 175, 105);border-style: dashed;border-width: 1px;padding: 5px 10px;background-color: rgba(232, 224, 65, 0);border-radius: 0.7em;height: auto;box-sizing: border-box;"><section style="text-align: justify;color: rgb(219, 175, 105);box-sizing: border-box;" powered-by="xiumi.us"><section style="margin-top: 0px;margin-bottom: 0px;padding: 0px;max-width: 100%;font-family: -apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size: 17px;letter-spacing: 0.544px;white-space: normal;background-color: rgb(255, 255, 255);opacity: 1;transform: rotateZ(0deg);-webkit-transform: rotateZ(0deg);-moz-transform: rotateZ(0deg);-o-transform: rotateZ(0deg);overflow-wrap: break-word !important;box-sizing: border-box;"><section style="margin: 10px 0px;padding: 0px;max-width: 100%;overflow-wrap: break-word !important;box-sizing: border-box;"><section style="margin: -15px 15px;padding: 0px;max-width: 100%;overflow-wrap: break-word !important;box-sizing: border-box;"><section style="margin: 0px;padding: 0px;max-width: 100%;letter-spacing: 2px;overflow-wrap: break-word !important;box-sizing: border-box;"><p style="padding: 0px;max-width: 100%;clear: both;min-height: 1em;text-align: left;overflow-wrap: break-word !important;margin: 0px;box-sizing: border-box;"><span style="margin: 0px;padding: 0px;max-width: 100%;font-size: 12px;letter-spacing: 1px;overflow-wrap: break-word !important;box-sizing: border-box;"><span style="margin: 0px;padding: 0px;max-width: 100%;vertical-align: inherit;overflow-wrap: break-word !important;box-sizing: border-box;"><span style="margin: 0px;padding: 0px;max-width: 100%;vertical-align: inherit;overflow-wrap: break-word !important;box-sizing: border-box;">References</span></span></span><span style="font-size: 12px;letter-spacing: 1px;box-sizing: border-box;">：</span></p><section style="margin: 5px 0px;padding: 0px;max-width: 100%;font-size: 12px;letter-spacing: normal;text-align: left;line-height: 1.75em;overflow-wrap: break-word !important;box-sizing: border-box;"><section style="margin: 0px;padding: 0px;max-width: 100%;display: inline-block;width: 416px;height: 240px;vertical-align: top;overflow-y: auto;overflow-wrap: break-word !important;box-sizing: border-box;"><section style="margin: 0px;padding: 0px;max-width: 100%;overflow-x: hidden;overflow-wrap: break-word !important;box-sizing: border-box;"><section style="margin: 0px;padding: 0px 8px;max-width: 100%;text-align: justify;overflow-wrap: break-word !important;box-sizing: border-box;"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[1] 康希诺生物股份公司2021年半年度报告 http://www.cansinotech.com.cn/upload/1/editor/1630246602542.pdf</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[2] 康希诺：关于持股5%以上股东减持股份计划公告http://www.cninfo.com.cn/new/disclosure/detail?stockCode=688185&announcementId=1210747354&orgId=9900038913&announcementTime=2021-08-14</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[3] 新浪财经：摩根大通减持康希诺770万股 套现28.87亿港元 https://finance.sina.com.cn/stock/hkstock/ggscyd/2021-06-25/doc-ikqcfnca3217199.shtml</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[4] 调研三人行：纪要：康希诺半年报会议交流纪要 https://mp.weixin.qq.com/s/AOu0XoPSN2B1IaKMaTIdTg</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[5] 中安在线：智飞生物新冠疫苗加速生产日产超过100万剂.2021-5-19 http://jx.ah.gov.cn/sy/syzx/qyfzxx/145787091.html</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[6] NMPA： 国家药监局附条件批准康希诺生物股份公司重组新型冠状病毒疫苗（5型腺病毒载体）注册申请 https://www.nmpa.gov.cn/yaowen/ypjgyw/20210225184523188.html</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[7] 智飞生物：关于重组新冠疫苗被纳入紧急使用的提示性公告 http://www.cninfo.com.cn/new/disclosure/detail?stockCode=300122&announcementId=1209401686&orgId=9900014108&announcementTime=2021-03-17</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[8] 贺梨萍：康希诺生物新冠疫苗三期生产基地产品下线：投入到大规模生产. 澎湃新闻. 2021-4-25</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[9] 唐强：智飞生物董事长亲测自家新冠疫苗 年产3亿剂疫苗生产线已建成. 证券时报-e公司. 2020-10-9 http://egs.stcn.com/news/detail/743454.html</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[10] 国泰君安：新冠疫情&新冠疫苗周度进展跟踪.2021-8-29</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[11] 国务院联防联控机制权威发布会（2021年8月27日）http://www.gov.cn/xinwen/gwylflkjz165/index.htm</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[12] WHO: Coronavirus disease (COVID-19): Vaccines https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[13] Reuters: WHO warns individuals against mixing and matching COVID vaccines https://www.reuters.com/business/healthcare-pharmaceuticals/who-warns-against-mixing-matching-covid-vaccines-2021-07-12/</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[14] CDC: Understanding mRNA COVID-19 Vaccines https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[15] Spencer, A.J., McKay, P.F., Belij-Rammerstorfer, S. et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat Commun 12, 2893 (2021). https://doi.org/10.1038/s41467-021-23173-1</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[16] Ewen Callaway. Mix-and-match COVID vaccines trigger potent immune response. Nature 593, 491 (2021) doi: https://doi.org/10.1038/d41586-021-01359-3</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[17] 国家卫健委 疾病预防控制局：新冠病毒疫苗接种情况（2021年8月31日）http://www.nhc.gov.cn/xcs/yqfkdt/202108/184ada26390546bc90cdabebe25fe5de.shtml</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[18] WHO: Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process(2021-8-19) https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_19August2021.pdf</p><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">[19] 国家药品监督管理局-药品查询- 脑膜炎</p></section></section></section></section></section></section></section></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><section style="box-sizing: border-box;"><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;"><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.188781" data-src="https://2-im.guokr.com/EgpNMmsOnDHKaEYSX1fBjk4YI9EuLRqm-pzVWOBwAZCfAwAArwAAAFBO.png" data-type="png" data-w="927" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;visibility: visible !important;width: 677px !important;height: auto !important;" src="https://2-im.guokr.com/EgpNMmsOnDHKaEYSX1fBjk4YI9EuLRqm-pzVWOBwAZCfAwAArwAAAFBO.png?imageView2/1/w/555/h/104" referrerpolicy="no-referrer"><br><br></section></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;border-width: 3px;border-radius: 15px;border-style: solid;border-color: rgb(37, 37, 37);overflow: hidden;box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650147830&idx=1&sn=9e266e0c6aa17acc0213a357d0daf550&chksm=f0167d16c761f400b08deec01f0ec384ee9baf6e4fe056523833716bfb4277401e37a4ddf665&scene=21#wechat_redirect" textvalue="你已选中了添加链接的内容" data-itemshowtype="0" tab="innerlink" data-linktype="1"><span class="js_jump_icon h5_image_link" data-positionback="static" style="inset: auto;margin: 0px;"><img data-croporisrc="https://mmbiz.qpic.cn/mmbiz_jpg/nY1TzTHeMNkH8LLORjyOmN5cFMib1gKHtpPans8F50xiaP1NtRDDLiaKhDs7ryzbSdaPxzoNYYHv0vtlJwJYAT4ag/0?wx_fmt=jpeg" data-cropx1="0" data-cropx2="900" data-cropy1="79.31654676258992" data-cropy2="304.3165467625899" data-ratio="0.24888888888888888" data-src="https://1-im.guokr.com/kaZjZum4bAFYCG6NbnIjZJDhbjKPRbIuzfPO3BuuSyWEAwAA4AAAAEpQ.jpg" data-type="jpeg" data-w="900" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;margin: 0px;visibility: visible !important;width: 556px;height: 139px;" src="https://1-im.guokr.com/kaZjZum4bAFYCG6NbnIjZJDhbjKPRbIuzfPO3BuuSyWEAwAA4AAAAEpQ.jpg?imageView2/1/w/555/h/138" referrerpolicy="no-referrer"></span></a></section></section><p style="text-align: center;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650147830&idx=1&sn=9e266e0c6aa17acc0213a357d0daf550&chksm=f0167d16c761f400b08deec01f0ec384ee9baf6e4fe056523833716bfb4277401e37a4ddf665&scene=21#wechat_redirect" textvalue="《寒武纪的最后一战》" data-itemshowtype="0" tab="innerlink" data-linktype="2"><span style="box-sizing: border-box;">《</span>寒武纪的最后一战<span style="box-sizing: border-box;">》</span></a></p><section style="box-sizing: border-box;"><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;border-width: 3px;border-radius: 15px;border-style: solid;border-color: rgb(37, 37, 37);overflow: hidden;box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650147805&idx=1&sn=9b6d67c04216806b41d6b114c750302b&chksm=f0167d3dc761f42b21c0683c108d2d4f7fc5f855c9a31da16197c15680fe0a5fa6b169616258&scene=21#wechat_redirect" data-itemshowtype="0" data-linktype="1"><span class="js_jump_icon h5_image_link" data-positionback="static" style="inset: auto;margin: 0px;"><img data-croporisrc="https://mmbiz.qpic.cn/mmbiz_jpg/nY1TzTHeMNmU9EQHJHNDkWLNMWWK5CRuXerTicWwLgXbTSQ9a1b0dBJWOribNLtOgNARDhD8TSG7x7okkp90Cu4Q/0?wx_fmt=jpeg" data-cropx1="0" data-cropx2="1175" data-cropy1="88.7589928057554" data-cropy2="382.5089928057554" data-ratio="0.24936170212765957" data-src="https://2-im.guokr.com/h73ULHF-pTQweOmMstSv5NhL4VyVTrVFPBMVMSjNkv84BAAADQEAAEpQ.jpg" data-type="jpeg" data-w="1175" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;margin: 0px;visibility: visible !important;width: 556px !important;height: auto !important;" src="https://2-im.guokr.com/h73ULHF-pTQweOmMstSv5NhL4VyVTrVFPBMVMSjNkv84BAAADQEAAEpQ.jpg?imageView2/1/w/555/h/138" referrerpolicy="no-referrer"></span></a></section></section><p style="text-align: center;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650147805&idx=1&sn=9b6d67c04216806b41d6b114c750302b&chksm=f0167d3dc761f42b21c0683c108d2d4f7fc5f855c9a31da16197c15680fe0a5fa6b169616258&scene=21#wechat_redirect" data-itemshowtype="0" data-linktype="2"><span style="box-sizing: border-box;">《勒索软件的2021：黑手从哪来，钱往哪里去？</span><span style="box-sizing: border-box;">》</span></a></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;border-width: 3px;border-radius: 15px;border-style: solid;border-color: rgb(37, 37, 37);overflow: hidden;box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650147773&idx=1&sn=13aaa0c8af848d123437511f1c8122ef&chksm=f0167d5dc761f44b93dedda8a2950bc89bb3a8c53564484aa190333f799280dd4a012621e268&scene=21#wechat_redirect" data-itemshowtype="0" data-linktype="1"><span class="js_jump_icon h5_image_link" data-positionback="static" style="inset: auto;margin: 0px;"><img data-croporisrc="https://mmbiz.qpic.cn/mmbiz_jpg/nY1TzTHeMNmmRPTQNfRHRItrBBC6oc1bvQhiczzOHWDrp2LkxTfFZIPe6RXI00DG22ZiabulibSOgkHYlHfs5Blog/0?wx_fmt=jpeg" data-cropx1="0" data-cropx2="762" data-cropy1="208.31654676258995" data-cropy2="398.81654676258995" data-ratio="0.24934383202099739" data-src="https://1-im.guokr.com/sSdOyR1I5BfcmfKJir91pq4oeO8okTn1NV6F22weyBH6AgAAvgAAAEpQ.jpg" data-type="jpeg" data-w="762" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;margin: 0px;visibility: visible !important;width: 556px !important;height: auto !important;" src="https://1-im.guokr.com/sSdOyR1I5BfcmfKJir91pq4oeO8okTn1NV6F22weyBH6AgAAvgAAAEpQ.jpg?imageView2/1/w/555/h/138" referrerpolicy="no-referrer"></span></a></section></section><section style="text-align: center;color: rgb(38, 38, 38);font-size: 14px;box-sizing: border-box;"><p style="margin: 0px;padding: 0px;box-sizing: border-box;"><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzIyNDA1MjExMQ==&mid=2650147773&idx=1&sn=13aaa0c8af848d123437511f1c8122ef&chksm=f0167d5dc761f44b93dedda8a2950bc89bb3a8c53564484aa190333f799280dd4a012621e268&scene=21#wechat_redirect" data-itemshowtype="0" data-linktype="2"><span style="box-sizing: border-box;">《</span>赢麻了的小米，应该感谢谁？<span style="box-sizing: border-box;">》</span></a><span style="box-sizing: border-box;"></span></p></section><br><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img data-ratio="0.9185185" data-src="https://3-im.guokr.com/cDVC5hYfyuGbvep5ohF7PSS4LJdRs7V6UnnK-1jOlFo4BAAA4AMAAFBO.png" data-type="png" data-w="1080" style="vertical-align: middle;max-width: 100%;box-sizing: border-box;visibility: visible !important;width: 677px !important;height: auto !important;" src="https://3-im.guokr.com/cDVC5hYfyuGbvep5ohF7PSS4LJdRs7V6UnnK-1jOlFo4BAAA4AMAAFBO.png?imageView2/1/w/555/h/509" referrerpolicy="no-referrer"></section></section></section><p style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;"><br></p></section></section>
                  
</div>
            